An attempt to improve the results of treatment for breast cancer complicated by lysis

Abstract

Lysis in locally advanced breast cancer (BC) is not a sign of tumor process dissemination. The correct elaboration of management tactics for such patients may achieve rather good early and late results. The doxorubicin + xeloda regimen for BC complicated by lysis has some advantage over the FAC regimen, without additionally increasing the rate of adverse reactions and worsening the quality of life